Asia Pharmaceutical Industries

asiapharma-syria.com

ASIA Pharmaceutical Industries is one of the pioneering pharmaceutical companies in Syria and the Middle East. Within two decades, a dedicated and highly qualified team of scientists and healthcare professionals has developed a world-class company that has been awarded international quality certificates: cGMPs, ISO 9001, ISO 14001 as well as the OHSAS 18001.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

DICERNA ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO ACT WAITING PERIOD FOR NOVO NORDISK TENDER OFFER TO ACQUIRE DICERNA

Dicerna Pharmaceuticals, Inc. | December 27, 2021

news image

Dicerna Pharmaceuticals, Inc. announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021. As previously announced on November 18, 2021, Novo Nordisk commenced a cash tender offer to purchase all outstanding shares of Dicerna common stock for $38.25 per share in cash, without interest and subject to any wit...

Read More

PHARMA TECH

BAYER AND MAMMOTH BIOSCIENCES TO COLLABORATE ON NOVEL GENE EDITING TECHNOLOGY

Bayer and Mammoth Biosciences | January 10, 2022

news image

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies. Mammoth Biosciences’ groundbreaking gene-editing technology is a key enabling technology, as well as a stand-alone therapeutic modality. It will significantly enhance Bayer’s efforts to develop tra...

Read More

PHARMA TITANS TEAM TO TACKLE COVID-19

Precision Vaccinations | April 14, 2020

news image

Considering the extraordinary humanitarian challenge of ending the ongoing coronavirus pandemic, two leading pharmaceutical companies believe establishing a collaboration is the best tactic for bringing a world-class vaccine. Announced in a joint press release on April 14, 2020, GSK and Sanofi said the ‘global access to COVID-19 vaccines is a priority and are committed to making any vaccine that is developed through the collaboration affordable to the public.’ ‘And through mech...

Read More

BUSINESS INSIGHTS

ASCLETIS ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATIONS FOR RITONAVIR IN MULTIPLE EUROPEAN COUNTRIES

Ascletis Pharma Inc. | February 14, 2022

news image

Ascletis Pharma Inc.announces that it has submitted marketing authorization applications for ritonavir in Germany, France, Ireland and United Kingdom through its agent in Europe. It is expected that more marketing authorization applications for ritonavir in certain other countries, including the ones in Europe, North America and Asian Pacific will soon be submitted. Ascletis has been in discussion with both domestic and international companies, including major multi-national...

Read More
news image

BUSINESS INSIGHTS

DICERNA ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO ACT WAITING PERIOD FOR NOVO NORDISK TENDER OFFER TO ACQUIRE DICERNA

Dicerna Pharmaceuticals, Inc. | December 27, 2021

Dicerna Pharmaceuticals, Inc. announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021. As previously announced on November 18, 2021, Novo Nordisk commenced a cash tender offer to purchase all outstanding shares of Dicerna common stock for $38.25 per share in cash, without interest and subject to any wit...

Read More
news image

PHARMA TECH

BAYER AND MAMMOTH BIOSCIENCES TO COLLABORATE ON NOVEL GENE EDITING TECHNOLOGY

Bayer and Mammoth Biosciences | January 10, 2022

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies. Mammoth Biosciences’ groundbreaking gene-editing technology is a key enabling technology, as well as a stand-alone therapeutic modality. It will significantly enhance Bayer’s efforts to develop tra...

Read More
news image

PHARMA TITANS TEAM TO TACKLE COVID-19

Precision Vaccinations | April 14, 2020

Considering the extraordinary humanitarian challenge of ending the ongoing coronavirus pandemic, two leading pharmaceutical companies believe establishing a collaboration is the best tactic for bringing a world-class vaccine. Announced in a joint press release on April 14, 2020, GSK and Sanofi said the ‘global access to COVID-19 vaccines is a priority and are committed to making any vaccine that is developed through the collaboration affordable to the public.’ ‘And through mech...

Read More
news image

BUSINESS INSIGHTS

ASCLETIS ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATIONS FOR RITONAVIR IN MULTIPLE EUROPEAN COUNTRIES

Ascletis Pharma Inc. | February 14, 2022

Ascletis Pharma Inc.announces that it has submitted marketing authorization applications for ritonavir in Germany, France, Ireland and United Kingdom through its agent in Europe. It is expected that more marketing authorization applications for ritonavir in certain other countries, including the ones in Europe, North America and Asian Pacific will soon be submitted. Ascletis has been in discussion with both domestic and international companies, including major multi-national...

Read More